We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+11.16%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$14.6B
AUM Growth
+$4.4B
(+43%)
Cap. Flow
+$3.17B
Cap. Flow
% of AUM
21.64%
Top 10 Holdings %
Top 10 Hldgs %
34.38%
Holding
1,185
New
178
Increased
767
Reduced
213
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$168M |
| 2 |
Texas Instruments
TXN
|
+$145M |
| 3 |
NVIDIA
NVDA
|
+$144M |
| 4 |
Broadcom
AVGO
|
+$131M |
| 5 |
Intel
INTC
|
+$121M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VanEck Gold Miners ETF
GDX
|
+$94.1M |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$53M |
| 3 |
Apple
AAPL
|
+$22.3M |
| 4 |
Microsoft
MSFT
|
+$17.4M |
| 5 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
+$14.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.54% |
| 2 | Financials | 17.43% |
| 3 | Healthcare | 6.14% |
| 4 | Energy | 3.08% |
| 5 | Industrials | 3.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Bristol-Myers Squibb
BMY
$130B
| $3.07M | 0.02% |
48,585
+3,373
| +7% | +$210K |
|
|
DRNA
477
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $3.06M | 0.02% |
119,857
+97,384
| +433% | +$2.49M |
|
|
APLS
478
DELISTED
Apellis Pharmaceuticals
APLS
| $3.06M | 0.02% |
71,412
+52,653
| +281% | +$2.49M |
|
479
Xerox
XRX
$421M
| $3.06M | 0.02% |
126,204
-101,859
| -45% | -$2.43M |
|
480
BioXcel Therapeutics
BTAI
$27.1M
| $3.06M | 0.02% |
4,433
+3,081
| +228% | +$2.48M |
|
|
IMGN
481
DELISTED
Immunogen Inc
IMGN
| $3.06M | 0.02% |
377,762
+298,247
| +375% | +$2.44M |
|
482
Energy Recovery
ERII
$463M
| $3.06M | 0.02% |
166,776
+142,699
| +593% | +$2.28M |
|
483
Allogene Therapeutics
ALLO
$670M
| $3.06M | 0.02% |
86,583
+52,585
| +155% | +$1.77M |
|
|
FOLD
484
DELISTED
Amicus Therapeutics
FOLD
| $3.05M | 0.02% |
309,072
+266,892
| +633% | +$4.13M |
|
485
Iovance Biotherapeutics
IOVA
$1.99B
| $3.04M | 0.02% |
96,049
+77,386
| +415% | +$3.21M |
|
486
Arrowhead Research
ARWR
$12.5B
| $3.04M | 0.02% |
45,792
+33,205
| +264% | +$2.58M |
|
487
Palo Alto Networks
PANW
$298B
| $3.03M | 0.02% |
56,430
-30,336
| -35% | -$1.8M |
|
488
Editas Medicine
EDIT
$433M
| $3.02M | 0.02% |
71,990
+56,935
| +378% | +$3.24M |
|
|
BPMC
489
DELISTED
Blueprint Medicines
BPMC
| $3.02M | 0.02% |
31,047
+22,919
| +282% | +$2.29M |
|
490
NextEra Energy
NEE
$178B
| $3.02M | 0.02% |
39,886
-6,429
| -14% | -$502K |
|
491
Baidu
BIDU
$37.8B
| $3.01M | 0.02% |
13,816
-5,410
| -28% | -$1.41M |
|
492
Medtronic
MDT
$109B
| $3M | 0.02% |
25,438
+3,252
| +15% | +$381K |
|
|
MRTX
493
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3M | 0.02% |
17,535
+13,623
| +348% | +$2.7M |
|
|
ARNA
494
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3M | 0.02% |
43,223
+29,749
| +221% | +$2.29M |
|
495
Coherus Oncology
CHRS
$227M
| $3M | 0.02% |
205,046
+162,719
| +384% | +$2.76M |
|
496
Honeywell
HON
$78.9B
| $3M | 0.02% |
14,642
+5,184
| +55% | +$1.01M |
|
|
MRSN
497
DELISTED
Mersana Therapeutics
MRSN
| $3M | 0.02% |
7,404
+6,161
| +496% | +$2.99M |
|
498
Replimune Group
REPL
$1B
| $2.99M | 0.02% |
98,032
+81,083
| +478% | +$3.04M |
|
|
VXRT
499
DELISTED
Vaxart
VXRT
| $2.99M | 0.02% |
494,339
+369,042
| +295% | +$2.84M |
|
500
Ultragenyx Pharmaceutical
RARE
$2.47B
| $2.99M | 0.02% |
26,245
+19,812
| +308% | +$2.7M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q1 2021 Portfolio in Review
As of Q1 2021, Rafferty Asset Management held 1,185 positions worth $14.6B, up 43% from $10.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Rafferty Asset Management deployed $3.17B of net new capital in Q1 2021, opening 178 new positions and adding to 767 existing holdings. Its largest new stake was Zscaler: 20,226 shares worth $3.47M.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 27% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was VanEck Gold Miners ETF, an estimated $94.1M trimmed.
- Rafferty Asset Management's largest Q1 2021 buy was Zscaler: 20,226 shares worth $3.47M.
- Rafferty Asset Management added most to Qualcomm in Q1 2021, an estimated $168M increase.
- Rafferty Asset Management's biggest Q1 2021 reduction was VanEck Gold Miners ETF, cutting an estimated $94.1M.
- Rafferty Asset Management fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $5.35M.
- Rafferty Asset Management's ten largest holdings make up 34% of its $14.6B portfolio in Q1 2021.
- Rafferty Asset Management opened 178 new positions and closed 26 in Q1 2021.
- Rafferty Asset Management's portfolio value rose 43% quarter-over-quarter to $14.6B.
Based on Rafferty Asset Management's 13F filing for Q1 2021, filed 10 May 2021.